Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$14.70
-0.16 (-1.08%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.65
$15.18
50-Day Range
$12.01
$16.90
52-Week Range
$10.41
$19.93
Volume
511,724 shs
Average Volume
843,503 shs
Market Capitalization
$983.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.29

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
160.4% Upside
$38.29 Price Target
Short Interest
Bearish
10.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.44mentions of Kura Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.12) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

570th out of 1,040 stocks

Pharmaceutical Preparations Industry

272nd out of 509 stocks

KURA stock logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

Circling Back On Kura Oncology
Recap: Kura Oncology Q3 Earnings
Preview: Kura Oncology's Earnings
Kura Oncology
Earnings Preview: Kura Oncology
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings
11/03/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.29
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+160.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-130,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.61 per share

Miscellaneous

Free Float
63,285,000
Market Cap
$983.39 million
Optionable
Optionable
Beta
0.85

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 53)
    Ph.D., Chairman, CEO, Pres & Principal Financial Officer
    Comp: $984.61k
  • Ms. Kathleen Ford (Age 75)
    Chief Operating Officer
    Comp: $689.32k
  • Dr. Marc Grasso M.D. (Age 48)
    Advisor
    Comp: $651.68k
  • Ms. Kirsten Flowers (Age 47)
    Chief Commercial Officer & Chief Corp. Strategy Officer
    Comp: $642.98k
  • Dr. Stephen Dale M.D. (Age 50)
    Chief Medical Officer
    Comp: $811.58k
  • Mr. Thomas Doyle (Age 51)
    Principal Accounting Officer & Sr. VP of Fin. and Accounting
  • Mr. Pete De Spain
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. James E. Basta J.D. (Age 56)
    Esq., Chief Compliance Officer & Corp. Sec.
  • Ms. Teresa Brophy Bair Esq. (Age 51)
    J.D., Chief Legal Officer & Corp. Sec.
  • Dr. Roger Bakale Ph.D.
    VP and Head of CMC, Clinical & Commercial Manufacturing













KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2023?

6 brokers have issued 1 year price targets for Kura Oncology's shares. Their KURA share price forecasts range from $26.00 to $80.00. On average, they anticipate the company's stock price to reach $38.29 in the next twelve months. This suggests a possible upside of 160.4% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2022?

Kura Oncology's stock was trading at $14.00 at the beginning of the year. Since then, KURA stock has increased by 5.0% and is now trading at $14.70.
View the best growth stocks for 2022 here
.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,980,000 shares, an increase of 11.0% from the October 31st total of 6,290,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 6.9 days. Currently, 10.8% of the company's shares are short sold.
View Kura Oncology's Short Interest
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.04.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.29%), State Street Corp (6.53%), Vanguard Group Inc. (4.92%), Balyasny Asset Management LLC (2.83%), Dimensional Fund Advisors LP (2.35%) and Victory Capital Management Inc. (2.03%). Insiders that own company stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $14.70.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $983.39 million. The company earns $-130,470,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Kura Oncology have?

The company employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 11/29/2022 by MarketBeat.com Staff